Drug Habits

Image source: New Africa, F16-ISO100 and Kwangmoozaa - Shutterstock

What's going on?

Pfizer announced plans on Tuesday to buy Biohaven Pharmaceutical in its biggest deal in five years.

What does this mean?

Pfizer’s facing an uphill battle going forward: sales of its Covid vaccine are expected to peter out sooner or later, and some of its biggest-selling cancer drugs are due to lose patent protection in the next few years. So the company’s putting some of its hard-profiteered cash to good use, having already bought drugmakers Trillium Therapeutics and Arena Pharmaceuticals late last year for around $2 billion and $7 billion respectively. It added to that roster on Tuesday, announcing plans to buy Biohaven Pharmaceutical in a deal worth almost $12 billion. The move will give Pfizer access to a migraine drug that brought in nearly $500 million in revenue last year, and is projected to bring in $1 billion by 2024.

Why should I care?

For markets: Patience is a virtue.
Pfizer’s putting up almost $149 for each of Biohaven’s shares – a hefty 78% more than they were worth before the deal was announced. Those kinds of premiums are a pretty standard way to convince the target’s shareholders to accept the deal, but Pfizer may have actually nabbed a bargain: Biohaven’s stock was trading at $143 as recently as mid-February.

The bigger picture: Better late than never, Novavax.
If Pfizer is the drugmaker that got the vaccine party started, Novavax is the one that turns up at midnight with a bottle of schnapps: the company reported its first profitable quarter this week, as its vaccines finally rolled out across the world (tweet this). The company was part of the US-backed race to develop a vaccine in 2020, but it missed out to the likes of Pfizer and Johnson & Johnson. Now, though, Novavax is hoping that its more traditional technology will appeal to holdouts, as though antivaxxers were only ever a protein-based solution away from civic-mindedness.

Originally posted as part of the Finimize daily email.

The top 2 financial news stories in 3 minutes. Join over one million Finimizers

Read next

Time Travel

Sign up to Finimize

Get the two most important global financial news stories each day. Sent at midnight UK time.

Get started with one email a day

The top financial news stories in 3 minutes.